Cargando…

The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites

Ivacaftor–lumacaftor and ivacaftor are two new breakthrough cystic fibrosis transmembrane conductance modulators. The interactions of ivacaftor and its two metabolites hydroxymethylivacaftor (iva-M1) and ivacaftorcarboxylate (iva-M6) with neurotransmitter receptors were investigated in radioligand b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schneider, Elena K., McQuade, Rachel M., Carbone, Vincenzo C., Reyes-Ortega, Felisa, Wilson, John W., Button, Brenda, Saito, Ayame, Poole, Daniel P., Hoyer, Daniel, Li, Jian, Velkov, Tony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850045/ https://www.ncbi.nlm.nih.gov/pubmed/29560360 http://dx.doi.org/10.1183/23120541.00127-2017

Ejemplares similares

Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis
por: Hanafin, Patrick O., et al.
Publicado: (2021)

Lumacaftor/ivacaftor-associated health stabilisation in adults with severe cystic fibrosis
por: King, Susannah J., et al.
Publicado: (2021)

Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination
por: Veit, Guido, et al.
Publicado: (2020)

Mu and Delta Opioid Receptors Are Coexpressed and Functionally Interact in the Enteric Nervous System of the Mouse Colon
por: DiCello, Jesse J., et al.
Publicado: (2019)

Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor
por: Schneider, Elena K.
Publicado: (2018)

Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis
por: Shanthikumar, Shivanthan, et al.
Publicado: (2022)

Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Lumacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability
por: Vonk, Steffie E. M., et al.
Publicado: (2021)

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
por: Pilewski, Joseph M., et al.
Publicado: (2020)

Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events
por: Schwarz, Carsten, et al.
Publicado: (2021)

Advantages and Disadvantages of Using Magnetic Nanoparticles for the Treatment of Complicated Ocular Disorders
por: Schneider-Futschik, Elena K., et al.
Publicado: (2021)

Bridging for lung transplantation with lumacaftor/ivacaftor
por: Pedersen, Søren Sperling, et al.
Publicado: (2018)

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021)

Ivacaftor decreases monocyte sensitivity to interferon-γ in people with cystic fibrosis
por: Hisert, Katherine B., et al.
Publicado: (2020)

Osteoarthritis of the Knee
por: McQuade, Jean
Publicado: (2015)

Compulsory Health Insurance
por: McQuade, Jerry
Publicado: (1920)

Digit ratio links prenatal hormone exposure with adult lung function
por: McQuade, Denise Brooks
Publicado: (2014)

Ivacaftor Therapy in CF Patients: Single Center Experience
por: Mondal, Pritish, et al.
Publicado: (2014)

Pancreatitis in A Patient with Cystic Fibrosis Taking Ivacaftor
por: Petrocheilou, Argyri, et al.
Publicado: (2020)

Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections
por: Durfey, Samantha L., et al.
Publicado: (2021)

Secretion Systems and Secreted Proteins in Gram-Negative Entomopathogenic Bacteria: Their Roles in Insect Virulence and Beyond
por: McQuade, Rebecca, et al.
Publicado: (2018)

Solvent Retention and Crack Evolution in Dropcast PEDOT:PSS and Dependence on Surface Wetting
por: McQuade, James, et al.
Publicado: (2018)

Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis
por: Han, Xiaoxuan, et al.
Publicado: (2023)

An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin
por: Yuan, Huiya, et al.
Publicado: (2021)

Ivacaftor in severe cystic fibrosis lung disease and a G551D mutation
por: Wood, Michelle E, et al.
Publicado: (2013)

Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis
por: O’Reilly, Ruth, et al.
Publicado: (2013)

The use of ivacaftor in CFTR mutations resulting in residual functioning protein
por: Guigui, S., et al.
Publicado: (2016)

Potentiation of ABCA3 lipid transport function by ivacaftor and genistein
por: Kinting, Susanna, et al.
Publicado: (2019)

Pharmacokinetic and Drug–Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor
por: Garg, Varun, et al.
Publicado: (2019)

Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation
por: Ooi, Chee Y., et al.
Publicado: (2018)

Sustained Glycemic Control With Ivacaftor in Cystic Fibrosis–Related Diabetes
por: Christian, Francis, et al.
Publicado: (2019)

Combination Therapy with Lumacaftor–Ivacaftor in Cystic Fibrosis. Keeping It Real
por: Sala, Marc A., et al.
Publicado: (2020)

Ivacaftor Inhibits Glioblastoma Stem Cell Maintenance and Tumor Progression
por: Liu, Kun, et al.
Publicado: (2021)

Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis
por: Mésinèle, Julie, et al.
Publicado: (2022)

Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
por: Zhang, Lijia, et al.
Publicado: (2022)

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
por: Tümmler, Burkhard
Publicado: (2023)

Impact of pharmacy services on time to elexacaftor-tezacaftor-ivacaftor initiation
por: Roder, Lauren, et al.
Publicado: (2022)

Beneficial Effects of Capsaicin in Disorders of the Central Nervous System
por: Pasierski, Michał, et al.
Publicado: (2022)

Sputum Active Polymyxin Lipopeptides: Activity against Cystic Fibrosis Pseudomonas aeruginosa Isolates and Their Interactions with Sputum Biomolecules
por: Schneider-Futschik, Elena K., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hvp6n3n1u4pvvt3hsfp295hdcf